造血干细胞移植治疗外周T细胞淋巴瘤研究进展

Progress of hematopoietic stem cell transplantation in treatment of peripheral T⁃cell lymphoma

外周T细胞淋巴瘤(PTCL)是一组高度异质性的恶性淋巴增殖性疾病,临床较为少见,常规综合治疗有效率低,转归差。造血干细胞移植(HSCT)能明显改善PTCL患者的生存,既往研究认为对于诊断明确的患者在诱导治疗得到缓解后应接受高剂量化疗联合自体造血干细胞移植(auto-HSCT),但目前auto-HSCT作为PTCL患者一线巩固治疗仍存在争议。对于复发难治PTCL,auto-HSCT疗效欠佳,异基因造血干细胞移植是一种有效的选择。文章对HSCT治疗PTCL的研究进展进行阐述。

Peripheral T-cell lymphoma(PTCL)is a group of highly heterogeneous rare malignant lymphoproliferative diseases,and PTCL patients have low therapeutic efficacy rate and poor prognosis after conventional comprehensive treatments.Hematopoietic stem cell transplantation(HSCT)can improve the survival of PTCL patients,and previous studies showed that patients with a definite diagnosis should receive high-dose chemotherapy combined with autologous-HSCT(auto-HSCT)in the first remission.In recent years,a consensus on the role of auto-HSCT as the first-line consolidation therapy for PTCL patients has not been reached so far.Allogeneic-HSCT is an effective option for relapsed and refractory patients with PTCL,while auto-HSCT has unfavorable efficacies.This paper reviews the research progress of HSCT in treatment of PTCL.